P4, N=150, Recruiting, Montefiore Medical Center | Not yet recruiting --> Recruiting

P1, N=168, Not yet recruiting, The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University

P=N/A, N=60, Recruiting, Beijing Chao Yang Hospital

The ECM architecture is dynamically modulated by multiple serine proteases that process both structural and signaling proteins to regulate physiological processes such as organogenesis and tissue homeostasis but they also contribute to pathological events, especially cancer progression. Here, we review the current literature regarding the role of ECM remodeling by serine proteases (KLKs, uPA, furin, HtrAs, granzymes, matriptase, hepsin) in tumorigenesis.

Taken together, NM enhanced the CBP sensitivity of ovarian cancer cells by promoting the ZNF24-mediated inactivation of the WNT2B/Wnt/β-catenin axis. These findings suggest a viable treatment approach for improving CBP resistance in ovarian cancer.

P3, N=37, Active, not recruiting, Takeda | Enrolling by invitation --> Active, not recruiting

The structure shows that serpin B9 adopts a relaxed conformation, with its cleaved reactive-centre loop inserted into the central β-sheet. Unlike other serpins, serpin B9 shows significant structural deviations around helix D, with a larger surface cavity, which could serve as a promising target for small-molecule inhibitors.

P4, N=62, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting

P3, N=40, Not yet recruiting, Hamilton Health Sciences Corporation

P=N/A, N=1000, Recruiting, Takeda | Not yet recruiting --> Recruiting

P1, N=17, Completed, Ensysce Biosciences | Phase classification: P1b --> P1

P2, N=150, Recruiting, University of California, San Francisco | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

P=N/A, N=534, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi

P3, N=220, Recruiting, Elsan | Trial completion date: Jul 2025 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025

TMPRSS4 is a potential prognostic biomarker of radical resection for BTC.

HC-HA/PTX3 was purified from UC extract by successive runs of density gradient ultracentrifugation and verified the presence of HC1 but not HC2 or HC3 based on western blot analysis. These results suggest the presence of HC-HA/PTX3 complex in UC is similar to AM.

P1, N=12, Not yet recruiting, The University of Texas Health Science Center at San Antonio

P3, N=150, Recruiting, ApcinteX Ltd

P4, N=500, Recruiting, University of Michigan | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P=N/A, N=166, Recruiting, Talphera, Inc | Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Dec 2024 | Initiation date: Mar 2024 --> Aug 2024 | Trial primary completion date: Aug 2024 --> Dec 2024

P2, N=108, Terminated, University Hospital, Ghent | Recruiting --> Terminated; Interim analyses did not show evidence that camostat mesylate under the present conditions (300 mg three times daily for five or 10 consecutive days, fasted state) was effective as an antiviral drug against early phase SARS-CoV-2 disease.

P2, N=32, Recruiting, Bioxodes S.A. | Active, not recruiting --> Recruiting

In combination with the PI-RADS score, the biomarkers improve the detection of prostate carcinoma-free men (AUC = 0.89) and of those with clinically significant PCa (AUC = 0.93). We have uncovered the potential of urinary biomarkers for a test that allows a more stringent prioritization of mpMRI use and improves the decision criteria for prostate biopsy, minimizing patient burden by decreasing the number of unnecessary prostate biopsies.

P3, N=80, Recruiting, Assiut University | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025

P=N/A, N=100, Recruiting, Wonju Severance Christian Hospital | Enrolling by invitation --> Recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025

The findings indicate that PRSS8 contributes to the acquisition of resistance to gefitinib in NSCLC, potentially through regulation of the AKT/mTOR signaling pathway.

P=N/A, N=56, Not yet recruiting, Cairo University

P=N/A, N=1000, Not yet recruiting, Takeda

P2, N=8, Active, not recruiting, Bioxodes S.A. | Recruiting --> Active, not recruiting | N=32 --> 8

P2, N=112, Completed, Palisade Bio | Recruiting --> Completed | N=200 --> 112 | Trial primary completion date: Jun 2023 --> Sep 2023

P3, N=59, Terminated, Institut Pasteur de Dakar | N=186 --> 59 | Recruiting --> Terminated; In conclusion, the results of the SEN-CoV Fadj trial to date do not meet the objectives of the clinical trial and the sample size required to meet them is clearly too large to be achieved within a reasonable time.

P2, N=32, Recruiting, Bioxodes S.A. | Initiation date: Jul 2023 --> Nov 2023

P3, N=23, Terminated, Palisade Bio | N=600 --> 23 | Trial completion date: Sep 2024 --> Aug 2023 | Active, not recruiting --> Terminated; Company decision

P4, N=150, Not yet recruiting, Montefiore Medical Center

P2/3, N=61, Terminated, RedHill Biopharma Limited | N=310 --> 61 | Suspended --> Terminated; Part A complete; corporate decision made to cancel Part B.

P=N/A, N=102, Completed, Acibadem University | Recruiting --> Completed

P4, N=100, Recruiting, University of Virginia

Suppression of SPINK1 inhibited OTSCC cell proliferation, invasion, and motility while promoting apoptosis. These findings suggest that SPINK1 may serve as a prognostic biomarker as well as a potential therapeutic target for managing OTSCC.

The in vitro tumor-promoting potency of CORIN could be antagonized by selective inhibitors targeting the ERK1/2 MAPK pathway. In conclusion, CORIN is a potential prognostic marker and therapeutic target for GC patients, which may promote tumor progression by mediating the ERK1/2 MAPK signaling pathway and EMT in GC cells.

Finally, we determined the rTMPRSS2_SP stability for long-term storage. Altogether, our results represent the first comprehensive characterization of TMPRSS2's biochemical properties, providing valuable insights into its serine protease domain.

TMPRSS4 can be considered a prognostic factor and therapeutic target for pancreatic ductal adenocarcinoma.

P3, N=100, Recruiting, Hospital for Special Surgery, New York | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025